Diurnal Group plc

AIM:DNL Stock Report

Market Cap: UK£47.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Diurnal Group Valuation

Is DNL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DNL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DNL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DNL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DNL?

Key metric: As DNL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DNL. This is calculated by dividing DNL's market cap by their current revenue.
What is DNL's PS Ratio?
PS Ratio10.2x
SalesUK£4.68m
Market CapUK£47.74m

Price to Sales Ratio vs Peers

How does DNL's PS Ratio compare to its peers?

The above table shows the PS ratio for DNL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.7x
TRX Tissue Regenix Group
1xn/aUK£22.8m
AREC Arecor Therapeutics
3.1x-10.82%UK£15.9m
DEST Destiny Pharma
3.5x-171.36%UK£4.5m
OPTI OptiBiotix Health
31.4xn/aUK£17.9m
DNL Diurnal Group
10.2x62.15%UK£47.7m

Price-To-Sales vs Peers: DNL is good value based on its Price-To-Sales Ratio (10.2x) compared to the peer average (19x).

Price to Sales Ratio vs Industry

How does DNL's PS Ratio compare vs other companies in the GB Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
2x3.85%US$1.83b
OXB Oxford Biomedica
2.5x16.52%US$433.04m
TRX Tissue Regenix Group
1xn/aUS$30.58m
AREC Arecor Therapeutics
3.1x-10.82%US$21.28m
DNL 10.2xIndustry Avg. 7.3xNo. of Companies8PS020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DNL is good value based on its Price-To-Sales Ratio (10.2x) compared to the European Biotechs industry average (13.1x)

Price to Sales Ratio vs Fair Ratio

What is DNL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DNL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.2x
Fair PS Ratio21.7x

Price-To-Sales vs Fair Ratio: DNL is good value based on its Price-To-Sales Ratio (10.2x) compared to the estimated Fair Price-To-Sales Ratio (21.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DNL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
May ’26n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Apr ’26n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Mar ’26n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Feb ’26n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Jan ’26n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Dec ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Nov ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Oct ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Sep ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Aug ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Jul ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Jun ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
May ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Apr ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Mar ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Feb ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Jan ’25n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Dec ’24n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Nov ’24n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Oct ’24n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Sep ’24n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Aug ’24n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Jul ’24n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
Jun ’24n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2
May ’24n/a
UK£0.69
0%
60.00%UK£1.10UK£0.28n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/02 08:56
End of Day Share Price 2022/11/01 00:00
Earnings2022/06/30
Annual Earnings2022/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Diurnal Group plc is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian WhiteCantor Fitzgerald Europe
Michael FosterHardman & Co.
Michael MitchellPanmure Liberum Historic (Panmure Gordon)